Phase I and Pharmacologic Study of the Human DNA Methyltransferase Antisense Oligodeoxynucleotide MG98 given as a 21-day Continuous Infusion Every 4 Weeks
- 1 February 2003
- journal article
- clinical trial
- Published by Springer Nature in Investigational New Drugs
- Vol. 21 (1) , 85-97
- https://doi.org/10.1023/a:1022976528441
Abstract
Purpose:MG98 is a second generation phosphorothioate antisense oligodeoxynucleotide which is a highly specific inhibitor of translation of the mRNA for human DNA MeTase I (DNMT 1). This phase I...Keywords
This publication has 35 references indexed in Scilit:
- Inactivation of the DNA-Repair GeneMGMTand the Clinical Response of Gliomas to Alkylating AgentsNew England Journal of Medicine, 2000
- A bird's eye view of global methylationNature Genetics, 2000
- Aberrant CpG-island methylation has non-random and tumour-type–specific patternsNature Genetics, 2000
- A role for methylation of the hMLH1 promoter in loss of hMLH1 expression and drug resistance in ovarian cancerOncogene, 1999
- The DNA methylation paradoxPublished by Elsevier ,1999
- DNA (cytosine-5)-methyltransferases in mouse cells and tissues. studies with a mechanism-based probeJournal of Molecular Biology, 1997
- The DNA methylation machinery as a target for anticancer therapyPharmacology & Therapeutics, 1996
- DNA methylation properties: consequences for pharmacologyTrends in Pharmacological Sciences, 1994
- Cloning and sequencing of a cDNA encoding DNA methyltransferase of mouse cellsJournal of Molecular Biology, 1988
- Estimation of Small Percentages of Fœtal HæmoglobinNature, 1959